News & Views | Published:

Transplantation

BENEFIT of belatacept: kidney transplantation moves forward

Nature Reviews Nephrology volume 12, pages 261262 (2016) | Download Citation

New data from the BENEFIT study demonstrate that belatacept improves long-term allograft and patient survival after kidney transplantation, despite higher rates of biopsy-proven acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a feasible strategy to further the development of innovator drugs to reduce late graft loss.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Belatacept and long-term outcomes in kidney transplantation. N. Engl. J. Med. 374, 333–343 (2016).

  2. 2.

    , & Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11, 450–462 (2011).

  3. 3.

    et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535–546 (2010).

  4. 4.

    et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547–557 (2010).

  5. 5.

    , , , & Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 85, 258–264 (2014).

  6. 6.

    et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am. J. Transplant. 13, 2875–2883 (2013).

  7. 7.

    , , & Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378, 1419–1427 (2011).

  8. 8.

    , , , & Summary of the US FDA approval of belatacept. Am. J. Transplant. 12, 554–562 (2012).

  9. 9.

    & The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am. J. Transplant. 10, 1163–1166 (2010).

  10. 10.

    et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308, 2594–2604 (2012).

Download references

Author information

Affiliations

  1. Department of Microbiology and Immunology, KU Leuven – University of Leuven, Herestraat 49, 3000 Leuven, Belgium.

    • Maarten Naesens
  2. Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, HCL, 5 Place d'Arsonval, 69003 Lyon, France.

    • Olivier Thaunat

Authors

  1. Search for Maarten Naesens in:

  2. Search for Olivier Thaunat in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Maarten Naesens.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrneph.2016.34

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing